

## New pyrrolidone, imidazolone, furanon or thiophenone derivativ s

Patent Number: DE19626701

Publication  
date: 1998-01-08

Inventor(s): WEHNER VOLKMAR DR (DE); KNOLLE JOCHEN DR (DE); STILZ HANS ULRICH DR (DE); CARNIATO DENIS DR (FR); GOURVEST JEAN-FRANCOIS DR (FR); GADEK TOM DR (US); MCDOWELL ROBERT DR (US)

Applicant(s): HOECHST AG (DE)

Requested  
Patent: ☐ DE19626701

Application  
Number: DE19961026701 19960703

Priority Number  
(s): DE19961026701 19960703

IPC C07D233/76; C07D403/12; A61K31/47; A61K31/415; A61K31/44; A61K31/425;  
Classification: A61K31/505; C07K5/06; C07D521/00

EC  
Classification: C07D233/96, C07D403/12, C07D471/10

Equivalents:

### Abstract

5-Membered azacyclic derivatives (I) and their salts are new. W = C(R<16>)-D-B-A-R<1> (a), C=C(R<16>)-D-B-A-R<1> (b) or a group of formula (c) or (d); the ring of formula (e) is saturated or partly or fully unsaturated, and optionally contains 1 or 2 N, O and/or S atoms and is optionally mono-, di- or trisubstituted by R<16> or mono- or disubstituted by =Q; Y = CQ or CH<sub>2</sub>; Z = N(R<0>), Q or CH<sub>2</sub>; A = bond, 1-8C alkanediyl, CR<2>=NNR<2>, NR<2>CQNR<2>, QCQ'NR<2>, NR<2>S(O)nNR<2>, OS(O)nNR<2>, S(O)nNR<2>, 3-12 cycloalkanediyl, C?=C, NR<2>CO, CONR<2>, NR<2>CO-5-14C arylene, O, S(O)n, 5-14C arylene, CO, CO-5-14C arylene, NR<2>, NR<2>SO<sub>2</sub>, OCO, COO, N=CR<2> CR<2>=N, CR<2>=CR<3> or S(O)n-5-14C arylene (all optionally substituted by NR<2> and/or by 1 or 2 1-8C alkanediyl); Q, Q' = O or S; B = bond, 1-8C alkanediyl, 5-10C arylene, 3-8C cycloalkanediyl, C?=C, NR<2>, CO, CONR<2>, NR<2>CO, NR<2>-CQ-NR<2>, OCO, COO, SO, SO<sub>2</sub>, SONR<2>, SO<sub>2</sub>NR<2>, NR<2>SO, NR<2>SO<sub>2</sub>, Q or CR<2>=CR<3> (all optionally mono- or disubstituted by 1-6C alkanediyl) or a divalent residue of a 5-6 membered saturated or unsaturated ring containing 1 or 2 N atoms (optionally mono- or disubstituted substituted by 1-6C alkyl or =Q); D, F = bond, 1-8C alkanediyl, 5-10C arylene, Q, NR<2>, CONR<2>, NR<2>CO, NR<2>CQNR<2>, OCO, COO, CQ, SO, SO<sub>2</sub>, SO<sub>2</sub>NR<2>, NR<2>SO, NR<2>SO<sub>2</sub>, CR<2>=CR<3>, C?=C, CR<2>=NNR<2>, N=CR<2>, CR<2>=N or CHOH (all optionally mono- or disubstituted by 1-8C alkanediyl, CR<2>=CR<3> or 5-6C arylene); E = bond, 1-6C alkanediyl, 2-6C alkenediyl, 2-6C alkynediyl, phenylene, phenylene-1-3C alkanediyl or 1-3C alkanediyl-phenylene; G = CR<4>R<5>(CR<6>R<7>)p(CH<sub>2</sub>)qR<10>; L = C(R<16>) or N; R<0> = H, 1-8C alkyl (optionally substituted by 3-12C cycloalkyl or 5-14C aryl), 1-8C alkylcarbonyl, 3-12C cycloalkyl-carbonyl, (3-12C cycloalkyl- or 5-14C aryl-substituted) 1-6C alkylcarbonyl, 5-14C aryl-carbonyl, 3-12C cycloalkyl or 5-14C aryl (where all alkyl are optionally substituted by 1 or more F); R<1> = NR<2>CR<2>(=NR<2>), C(=NR<2>)NR<2>R<3>, NR<2>C(=NR<2>)NR<2>R<3>, or a 4-14 membered mono- or polycyclic optionally aromatic ring (optionally containing 1-4 N, O and/or S and optionally substituted by R<12>-R<15>); R<2>, R<3> = H, 1-10C alkyl (optionally substituted by 1 or more F), 3-12C cycloalkyl, 3-12C cycloalkyl-1-8C alkyl, 5-14C aryl, 5-14C aryl-1-8C alkyl, NH<sub>2</sub>; NR<9>OR<8>, R<9>OR<8>, R<9>COOR<8>, R<9>-5-14C aryl-R<8>, R<9>N(R<8>)<sub>2</sub>, R<9>-NR<8>-(1-8C hydroxyalkyl), R<9>CON(R<8>)<sub>2</sub>, R<9>NR<8>COR<8>, R<9>COR<sub>8</sub>, C(=NR<8>)N(R<8>)<sub>2</sub>; NR<8>C(=NR<8>)N(R<8>)<sub>2</sub> or (1-18C alkyl)-COO-1-6C alkoxy carbonyl; R<4>-R<7> = H, F, OH, 1-8C alkyl, 3-12C cycloalkyl, 3-12C cycloalkyl-1-8C alkyl, R<9>QR<8>, R<9>OCOR<8>, R<9>COOR<8>, R<9>-5-14C aryl-R<8>, R<9>N(R<2>)R<8>, R<9>N(R<8>)<sub>2</sub>, R<9>OCONR<8>R<2>, R<9>N(R<2>)S(O)nR<8>, R<9>NR<2>COQR<8>, R<9>NR<2>COR<8>, R<9>N(R<2>)CON(R<2>)R<8>, R<9>N(R<2>)S(O)

nNR<2>R<8>, R<9>S(O)nR<8>, R<9>NR<2>COSR<8>, R<9>COR<8>, R<9>CONR<2>R<8> or R<9>S(O)nNR<2>R<8>; R<8> = H, 1-8C alkyl (optionally substituted by 3-12C cycloalkyl or 5-14C aryl), 3-12C cycloalkyl or 5-14C aryl (where all alkyl are optionally substituted by 1 or more F); R<9> = bond or 1-8C alkanediyl; R<10> = CQR<11>, S(O)nR<11>, P(O)nR<11> or a 4-8 membered saturated or unsaturated heterocycle containing 1-4 N, O and/or S atoms; R<11> = OH, 1-8C alkoxy, 5-14C aryl-1-8C alkoxy, 5-14C aryloxy, 1-8C alkylcarbonyloxy-1-4C alkoxy, 5-14C aryl-1-8C alkylcarbonyloxy-1-4C alkoxy, NH<sub>2</sub>, mono- or di-1-8C alkylamino, 5-14C aryl-1-8C alkylamino, 1-8C dialkylaminocarbonylmethoxy, 5-14C aryl-1-8C dialkylaminocarbonylmethoxy, 5-14C arylamino or a D- or L-amino acid; R<12>-R<15> = H, 1-10C alkyl (optionally substituted by one or more F), 3-12C cycloalkyl, 3-12C cycloalkyl-1-8C alkyl, 5-14C aryl, 5-14C aryl-1-8C alkyl, NH<sub>2</sub>, R<9>OR<8>, R<9>COOR<8>, R<9>N(R<8>)<sub>2</sub>, R<9>-5-14C aryl-R<8>; R<9>-NR<2> (1-8C hydroxyalkyl), R<9>CON(R<2>)R<8>, R<9>N(R<2>)COR<8>, R<9>COR<8>, NR<2>C(=NR<3>)-NR<2>R<3>, C(=NR<2>)NR<2>R<3> or Q; or 2 of R<12>-R<15> which are adjacent form -OCH<sub>2</sub>O-, -OCH<sub>2</sub>CH<sub>2</sub>O- or -OC(CH<sub>3</sub>)<sub>2</sub>O-; R<16> = H, 1-10C alkyl optionally substituted by 1 o

Data supplied from the esp@cenet database - l2



⑨ BUNDESREPUBLIK  
DEUTSCHLAND



DEUTSCHES  
PATENTAMT

⑫ Off n l gungsschrift  
⑩ DE 196 26 701 A 1

⑳ Aktenzeichen: 196 26 701.3  
㉑ Anmeldetag: 3. 7. 96  
㉒ Offenlegungstag: 8. 1. 98

㉓ Int. Cl.<sup>6</sup>:  
C 07 D 233/76  
C 07 D 403/12  
A 61 K 31/47  
A 61 K 31/415  
A 61 K 31/44  
A 61 K 31/425  
A 61 K 31/505  
C 07 K 5/06  
// C07D 521/00  
(C07D 403/12, 233:76,  
249:08)


DE 196 26 701 A 1

㉔ Anmelder:  
Hoechst AG, 65929 Frankfurt, DE

㉕ Erfinder:  
Wehner, Volkmar, Dr., 97657 Sandberg, DE; Knolle,  
Jochen, Dr., 65830 Kriftel, DE; Stilz, Hans Ulrich, Dr.,  
65929 Frankfurt, DE; Carniato, Denis, Dr.,  
Marcoussis, FR; Gourvest, Jean-Francois, Dr., Claye  
Souilly, FR; Gadek, Tom, Dr., Oakland, Ca., US;  
McDowell, Robert, Dr., San Francisco, Ca., US

㉖ Neue Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten

㉗ Gegenstand der vorliegenden Erfindung sind 5-Ring-Heterocyclen der allgemeinen Formel I,



in der E, F, G, W, Y und Z die in den Patentansprüchen angegebenen Bedeutungen besitzen, ihre Herstellung, ihre Verwendung als Heilmittel und sie enthaltende pharmazeutische Zubereitungen. Die Verbindungen der Formel I wirken insbesondere als Vitronectinrezeptor-Antagonisten und Inhibitoren der Knochenresorption durch Osteoclasten.

DE 196 26 701 A 1